Your browser is no longer supported. Please, upgrade your browser.
Vaccitech plc
Index- P/E- EPS (ttm)-1.35 Insider Own0.10% Shs Outstand34.84M Perf Week1.07%
Market Cap328.23M Forward P/E- EPS next Y-0.93 Insider Trans46.28% Shs Float24.10M Perf Month-7.36%
Income-46.20M PEG- EPS next Q-0.31 Inst Own9.50% Short Float0.19% Perf Quarter-31.33%
Sales0.60M P/S547.05 EPS this Y14.60% Inst Trans- Short Ratio1.91 Perf Half Y-36.09%
Book/sh6.94 P/B1.36 EPS next Y45.90% ROA- Target Price24.00 Perf Year-
Cash/sh6.73 P/C1.40 EPS next 5Y- ROE- 52W Range7.50 - 17.99 Perf YTD-15.03%
Dividend- P/FCF- EPS past 5Y- ROI-221.30% 52W High-47.53% Beta-
Dividend %- Quick Ratio38.60 Sales past 5Y- Gross Margin- 52W Low25.87% ATR0.79
Employees48 Current Ratio38.60 Sales Q/Q-99.40% Oper. Margin- RSI (14)37.41 Volatility3.28% 8.04%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.02 Prev Close9.61
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume23.72K Price9.44
Recom1.60 SMA20-10.82% SMA50-13.69% SMA200-31.62% Volume423 Change-1.77%
May-25-21Initiated William Blair Outperform
May-25-21Initiated Morgan Stanley Overweight $22
May-25-21Initiated Jefferies Buy $28
May-24-21Initiated H.C. Wainwright Buy $25
Jan-21-22 03:41AM  
Jan-18-22 03:00AM  
Jan-13-22 04:34PM  
Jan-10-22 10:00AM  
Dec-13-21 04:05PM  
Dec-07-21 08:00AM  
Nov-24-21 09:20AM  
Nov-12-21 08:00AM  
Nov-10-21 08:00AM  
Nov-04-21 04:00AM  
Oct-28-21 01:23PM  
Oct-18-21 08:00AM  
Oct-13-21 08:00AM  
Sep-13-21 12:38PM  
Sep-09-21 08:00AM  
Aug-12-21 08:00AM  
Jul-30-21 10:00AM  
Jul-08-21 08:00AM  
Jul-06-21 10:19AM  
Jun-20-21 08:00PM  
Jun-14-21 05:49PM  
Jun-01-21 08:00AM  
May-06-21 04:32PM  
May-04-21 05:07PM  
Apr-29-21 06:49PM  
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection; VTP-200 for the treatment of human papilloma virus infection; VTP-850 indicated for the treatment of prostate cancer; and VTP-600 for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hammacher AlexDirectorDec 31Buy10.861,00010,8601,000Jan 04 04:05 PM
Wright RobinDirectorDec 22Buy9.9710,00099,70034,506Dec 23 04:06 PM
DAWES KAREN ADirectorMay 04Buy17.001,70028,9001,700May 06 04:29 PM
Wright RobinDirectorMay 04Buy17.0014,000238,00024,506May 06 04:28 PM
Griffiths GrahamChief Business OfficerMay 04Buy17.001001,700100May 06 04:28 PM
Ellis ChristopherChief Operating OfficerMay 04Buy17.00751,27575May 06 04:27 PM
Scheeren JosephDirectorMay 04Buy17.003,00051,0003,000May 06 04:26 PM
Oxford Sciences Innovation plc10% OwnerMay 04Buy17.00600,00010,200,0008,797,770May 06 04:25 PM
Phillips Anne M.DirectorMay 04Buy17.003,00051,0003,000May 06 04:25 PM
M&G INVESTMENT MANAGEMENT LTD10% OwnerApr 30Buy14.40125,0001,800,0001,088,597May 03 03:20 PM